Abstract

Negamycin is a natural pseudodipeptide antibiotic with promising activity against Gram-negative and Gram-positive bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus, and good efficacy in infection models. It binds to ribosomes with a novel binding mode, stimulating miscoding and inhibiting ribosome translocation. We were particularly interested in studying how the small, positively charged natural product reaches its cytoplasmic target in Escherichia coli Negamycin crosses the cytoplasmic membrane by multiple routes depending on environmental conditions. In a peptide-free medium, negamycin uses endogenous peptide transporters for active translocation, preferentially the dipeptide permease Dpp. However, in the absence of functional Dpp or in the presence of outcompeting nutrient peptides, negamycin can still enter the cytoplasm. We observed a contribution of the DppA homologs SapA and OppA, as well as of the proton-dependent oligopeptide transporter DtpD. Calcium strongly improves the activity of negamycin against both Gram-negative and Gram-positive bacteria, especially at concentrations around 2.5 mM, reflecting human blood levels. Calcium forms a complex with negamycin and facilitates its interaction with negatively charged phospholipids in bacterial membranes. Moreover, decreased activity at acidic pH and under anaerobic conditions points to a role of the membrane potential in negamycin uptake. Accordingly, improved activity at alkaline pH could be linked to increased uptake of [3H]negamycin. The diversity of options for membrane translocation is reflected by low resistance rates. The example of negamycin demonstrates that membrane passage of antibiotics can be multifaceted and that for cytoplasmic anti-Gram-negative drugs, understanding of permeation and target interaction are equally important.

Highlights

  • Negamycin is a natural pseudodipeptide antibiotic with promising activity against Gram-negative and Gram-positive bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus, and good efficacy in infection models

  • To learn from nature, we studied the uptake of the natural product antibiotic negamycin across the cytoplasmic membrane of Escherichia coli

  • Pseudomonas aeruginosa strain PAO1 was inhibited, at higher concentrations (32 to 64 mg/ml), while the Gram-positive bacteria tested (i.e., Staphylococcus aureus strain ATCC 29213, Bacillus subtilis strain 168 trpC2) were not inhibited up to 64 mg/ml under these conditions (Table 1), demonstrating that negamycin is stronger against Gram-negatives

Read more

Summary

Introduction

Negamycin is a natural pseudodipeptide antibiotic with promising activity against Gram-negative and Gram-positive bacteria, including Enterobacteriaceae, Pseudomonas aeruginosa, and Staphylococcus aureus, and good efficacy in infection models. It binds to ribosomes with a novel binding mode, stimulating miscoding and inhibiting ribosome translocation. Negamycin cured systemic infections with E. coli, Klebsiella pneumoniae, Salmonella enterica serotype Typhi, Pseudomonas aeruginosa, and Staphylococcus aureus and demonstrated low acute toxicity [7, 8]. It is more potent against Gram-negative than against Gram-positive bacteria. Negamycin triggers miscoding at the eukaryotic ribosome as well and cured Duchenne muscular dystrophy in mice, which carried a nonsense mutation in the dystrophin gene [17, 18]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call